Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 4/20 | 1.00 |
| ▸ | GRIK2 | Q13002 | 4/20 | 1.00 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.96 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.96 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28902633 | 1.00 | GRIK1 (1.00) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL29156799 | 1.00 | GRIK1 (1.00) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL1662288 | 1.00 | GRIK1 (1.00) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL9005456 | 1.00 | GRIK1 (1.00) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL8386178 | 1.00 | GRIK1 (1.00) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL10715048 | 1.00 | GRIK1 (1.00) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL9005462 | 1.00 | GRIK1 (1.00) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL5888741 | 1.00 | GRIK1 (1.00) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL8091382 | 1.00 | GRIK1 (1.00) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL5888744 | 1.00 | GRIK1 (1.00) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109836368-A | A kind of preparation method of high-purity Liraglutide side chain | 美药星（南京）制药有限公司 | 2019-06-04 | — | — | CN | disclosed |
| EP-1748805-B1 | ABSORBABLE BIOCOMPATIBLE COATINGS | BIOINTERACTIONS LTD (GB) | 2009-07-29 | — | — | EP | disclosed |
| CN-1956742-A | Absorbable biocompatible materials | BIOINTERACTIONS LTD (GB) | 2007-05-02 | — | — | CN | disclosed |
| EP-1748805-A1 | ABSORBABLE BIOCOMPATIBLE MATERIALS | Biointeractions Ltd. (GB) | 2007-02-07 | — | — | EP | disclosed |
| US-20060134166-A1 | Absorbable biocompatible materials | BIOINTERACTIONS LTD. (GB) | 2006-06-22 | — | — | US | disclosed |
| WO-2005115492-A1 | ABSORBABLE BIOCOMPATIBLE MATERIALS | BIOINTERACTIONS LTD (GB) | 2005-12-08 | — | — | WO | disclosed |
| EP-0572167-B1 | Cosmetic composition | UNILEVER PLC (GB) | 1996-10-09 | — | — | EP | disclosed |
| EP-0572167-A1 | Cosmestic composition | UNILEVER PLC (GB) | 1993-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060134166-A1 | Absorbable biocompatible materials | ADM2, HDGF, SLC7A1 | GRIK1 3278/4885GRIK2 3220/4885SLC1A2 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.